Kornimate/medical-research-clean huggingface dataset:
distance-based cognitive-behavioural therapy for high anxiety sensitivity: a randomized controlled trial

Conditions: Anxiety Sensitivity

Summary: anxiety disorders are common pervasive conditions with serious psychosocial implications. anxiety sensitivity (as) is one individual characteristic that has been implicated in the onset and maintenance of anxiety disorders (schmidt et al., 1999). as is an enduring fear of anxiety-related arousal sensations (i.e., increased heart rate) that arises from the tendency to interpret these sensations catastrophically, believing that they will have serious physical, psychological, or social consequences (reiss, 1991). research has shown the efficacy of cbt in decreasing as among women with high as (watt et al., 2006). unfortunately, access to effective psychological treatments is limited by a number of barriers such as a lack of treatment availability or qualified clinicians in an area. as such, we are conducting a randomized controlled trial (rct) of the effectiveness of a distance-based cbt program on decreasing as among those with high as. a distance delivery approach (e.g., via telephone) is one way to minimize treatment barriers and increase access to care while still delivering empirically supported treatment. recent research suggests distance delivery is promising (lovell et al., 2006). the rct will consist of an eight-week structured cbt program based on watt and stewart's (2008) brief cbt for as. the program will include weekly modules on psychoeducation, cognitive restructuring, interoceptive exposure, and relapse prevention. participants with high as will be recruited and randomly assigned to the treatment condition or wait-list control (after twelve weeks the wait-list group will receive treatment). in the treatment condition, participants will be assigned weekly reading and homework from the treatment manual. in addition, a therapist will guide them through the treatment by providing individualized support and feedback through weekly half-hour telephone sessions. treatment outcomes will be assessed through changes in as levels and anxiety symptoms pre- to post-treatment. also, participants' satisfaction with the mode of treatment delivery will be assessed. we hypothesize that this treatment program will be effective in reducing high as and anxiety symptom frequency and severity. we also expect this project to yield information about the utility of distance treatment delivery for mental health care.


Eligibility criteria:
inclusion criteria: * over 18 years of age * high anxiety sensitivity exclusion criteria: * cannot speak english * illiteracy * poor physical health (i.e., inadvisable to participate in physical exercise) * engaged in another form of psychotherapy * using pharmacotherapy for less than 3 months * anyone who changes dose or type of pharmacotherapy during study * psychosis * suicidal ideation
investigation of the influence of the human microbiome on giant cell arteritis

Conditions: Giant Cell Arteritis

Summary: the longitudinal observational study aims to assess the impact of the microbiome especially the gut-microbiome in the emergence and course of giant cell arteritis (abbr. gca) patients. at diagnosis and 6 month follow up we will analyze the oral, blood and gut microbiome from gca patients and healthy controls. thereby identified potential candidate biota will be further analyzed for possible interactions and influence on the immune system.


Eligibility criteria:
inclusion criteria: • diagnosis of giant cell arteritis (only in one arm) exclusion criteria: * chronic infection (viral, fungi, bacteria) including human immunodeficiency viruses, hepatitis b/c * acute infection with usage of antibiotics less then 90 days before screening * major gastro-intestinal surgery \<5 years from screening * gastro-intestinal bleeding \<90 days before screening * inflammatory bowel disease (confirmed bioptically) * bulimia or anorexia nervosa * adipositas (body mass index ≥ 40) * intake of high dosage of probiotics (\>10\^9 colony forming units per day) \<90 days before screening * not controlled diabetes mellitus * malignancy within one year (except for squamous skin - and basal skin carcinoma without metastasis, cervix carcinoma with curative surgery, cutaneous t-cell lymphoma) * known abuse of alcohol oder drugs.

Keywords: microbiome
gait speed at discharge as a marker for readmission

Conditions: All Disease That May Require Acute Hospitalization Except for Phsychiatric Disease

Summary: the principal aim is to assess if a simple test, the time it takes to walk 10 meters for a patient about to be discharged after a hospital stay for an acute illness, is related to the risk of readmission.


Eligibility criteria:
inclusion criteria: * \>50 years of age patient discharged to home, or temporary short stay nursing home expected survival \>90 days the ability to read or understand the instructions and to give informed consent. exclusion criteria: * planned hospital stay, i.e. the patient was admitted electively the including investigator is directly involved in the care of the patient
study to investigate the potential health benefits of grapes seeds extract supplementation in the management of elevated blood pressure or stage 1 hypertension

Conditions: Elevated Blood Pressure; Hypertension

Summary: this study is a pragmatic, randomized, double-blind, placebo-controlled trial aimed at evaluating the potential health benefits of enovita® (standardized grape seed extract) supplementation in adults with elevated blood pressure or stage 1 hypertension. the primary objective is to assess the impact of enovita® on systolic and diastolic blood pressure over 8 weeks. secondary outcomes include changes in mood, emotional well-being, perceived stress, lipid profile, and systemic inflammation. the study will also monitor the safety and tolerability of enovita®.

hypertension is a major risk factor for cardiovascular diseases, and its early management is crucial. grape seed extract is a natural polyphenol-rich supplement that may offer antihypertensive benefits through its antioxidant, anti-inflammatory, and vasodilatory properties. this study aims to investigate the effectiveness of a standardized grape seeds extract, enovita® in reducing blood pressure in adults with elevated blood pressure or stage 1 hypertension. this is a pragmatic, randomized, double-blind, placebo-controlled trial involving two groups: the enovita® group receiving 150 mg of enovita® twice daily and the placebo group receiving matching placebo capsules. the intervention will last for 8 weeks. participants will be assessed at baseline, 4 weeks, and 8 weeks. the primary outcome is the change in systolic and diastolic blood pressure from baseline to 8 weeks. secondary outcomes include changes in mood (panas and wemwbs scores), perceived stress (psq-20 score), lipid profile (total cholesterol, ldl, hdl, triglycerides), and systemic inflammation (hs-crp levels). safety will be monitored through adverse event reporting and regular health assessments. this study will provide insights into the potential of enovita® as a natural intervention for managing mild hypertension and improving emotional well-being.

Eligibility criteria:
inclusion criteria: * adults aged 30 to 65 years. * diagnosed with elevated blood pressure (systolic 120-129 mmhg and diastolic \<80 mmhg) or stage 1 hypertension (systolic 130-139 mmhg or diastolic 80-89 mmhg), according to american heart association guidelines. * no use of antihypertensive medication in the past 3 months. * willing to comply with study procedures and follow-up visits. * able to provide written informed consent. exclusion criteria: * stage 2 hypertension (systolic bp ≥140 mmhg or diastolic bp ≥90 mmhg) at screening. * chronic kidney disease (egfr \< 60 ml/min/1.73 m²). * diabetes mellitus (hba1c ≥ 6.5%). * history of cardiovascular events (myocardial infarction, stroke) in the past 6 months. * known allergy to grape products. * current use of polyphenol supplements or similar herbal products. * pregnancy or breastfeeding. * participation in another clinical trial within the last 30 days.
imodium syrup versus imodium tablets for faecal incontinence

Conditions: Fecal Incontinence

Summary: faecal incontinence (fi) is a debilitating and often neglected problem. it can be defined as the loss of voluntary control of liquid or solid stool.it is estimated that 2-3% of western adults suffer from fi with prevalence increasing with age, further to this up to 50% of nursing home residents suffer too with it more common in females. aetiology is often multi-factoral, where obstetric anal sphincter injury is most common is females and iatrogenic anal sphincter injury is most common in males. loperamide (imodium) is a constipating agent used as first choice pharmacological agent due to its high efficacy. trials have suggested it thickens stool consistency and may raise resting anal sphincter pressure, associated with improved clinical function with a reduction in bowel frequency and urgency, a reduction in incontinence and less need for pads. loperamide is well tolerated but has been known to cause side effects of abdominal pain and distension, nausea and vomiting and constipation. imodium can be taken in two ways; as syrup (1mg/5mls) or tablets (2mg). there have been no comparative studies. side effects are mainly seen with the tablet form and so it is hypothesized that the syrup form is better tolerated because it is more accurately titrated to effect. this is a nhs funded single blinded, randomised, cross-over study to assess the clinical effects of imodium, in tablet and syrup form, on patients presenting with faecal incontinence. each subject will act as their own control. patients will be recruited through out-patient visits for their fi, where they will be made aware of the trial. during the trial they will be asked to fill out fi scoring questionnaires and quality of life scores. also they will undertake two assessments of anal physiology testing squeeze pressures, sensation and compliance at baseline and at the end after three months.


Eligibility criteria:
inclusion criteria: * aged 18 - 75 * severe faecal incontinence defined as greater than one episode per week of involuntary loss of either solid or liquid stool as demonstrated by means of a baseline bowel habit and a vaizey score of greater than 4. * competent and willing to fill in questionnaires and attend follow up clinics through out the study period. exclusion criteria: * alternating bowel habit, associated with symptoms of constipation. use of other regular or as required medications that may affect bowel function. (e.g. codeine phosphate). * patients with complete or partial spinal cord injuries including cauda equina syndrome. * active inflammatory bowel disease. * pregnancy * stoma in situ * psychiatric and physiological inability to comply with study protocol. * non english speakers (student project funding cannot cover interpreter and other costs) (application of criteria at the discretion of the investigating doctor at initial consultation)

Keywords: fecal incontinence
responsiveness of multiple balance assessment tools in patients with peripheral neuropathy

Conditions: Peripheral Neuropathy

Summary: their is limited literature available regarding the assessment of balance by fullerton advanced balance scale in patients with diabetic peripheral neuropathy, previous studies have only focused on the use of berg balance scale and mini-bestest. so, this study aims to assess the responsiveness and sensitivity of berg balance scale, mini-bestest, and fullerton advanced balance scale in the patients of diabetic peripheral neuropathy.

diabetes is a serious, long-term condition with a major impact on the lives and well-being of individuals, families, and societies worldwide. diabetic neuropathy is its most common clinical consequence. diabetic peripheral neuropathy (dpn) is defined as "the presence of symptoms and/or signs of peripheral nerve dysfunction in people with diabetes after the exclusion of other causes." a person with dpn is up to 20 times more likely to fall than a non-diabetic of the same age, making falls an even more significant therapeutic concern. as a result of decreased balance, people with dpn are predisposed to falls, which can lead to injury, decreased balance confidence, fear-related avoidance of activities, and decreased quality of life. so, this study aims to assess the responsiveness and sensitivity of berg balance scale, mini-bestest, and fullerton advanced balance scale in the population of dpn and it will also predict which of them is the most responsive and sensitive and first evaluates changes in balance of patients with dpn. after the comparison of responsiveness and sensitivity of these scales, it can predict the best tool for early assessment of balance impairment in the people with dpn. this study will be beneficial in early identification of fall risk and minimization of fall related injuries and complications.

Eligibility criteria:
inclusion criteria: * either gender. * age between 40 to 60 years * known history of diabetes mellitus treated with by oral hypoglycemic drugs or insulin therapy. * known case of diabetic peripheral neuropathy (dpn) * patients who met the criteria of dn4 scored equal or greater than 4. * patients who have positive sharpend romberg test. * balance impairment on bbs (21-40). exclusion criteria: * lower limb muscles strength less than 3 on manual muscle testing. * any inflammatory condition, congenital or acquired malformation, vestibular system pathologies. * contraindication for engaging in physical activity (osteoarthritis, orthostatic hypo tension or any acute illness).

Keywords: balance. diabetes diabetic peripheral neuropathy otago exercise plan
perfusion assessment using bold mri and pbv in endovascular treatment of peripheral arterial occlusive disease

Conditions: Peripheral Arterial Disease; Tissue Perfusion

Summary: current assessment of lower limb ischemia cannot reflect the location and degree of ischemia. tissue perfusion assessment was used in the diagnosis and treatment of lower limb ischemia in this project, and the quantitative evaluation of ischemia degree was realized by using its advantages of quantitative analysis and perfusion imaging.


Eligibility criteria:
inclusion criteria: * subject has been diagnosed as paod by symptom and imaging; * subject intends to take endovascular treatment in pumch; * subjects without heavy stenosis in infrapopliteal artery (stenosis\<30%), or with short length lesion(length≤5cm, stenosis≥30%); * age \> 35 and \< 80; * subject has been informed the study and has signed informed consent; exclusion criteria: * subject with mri contraindications or allergic to iodinated contrast medium; * subject underwent intervention therapy or angioplasty in target vessel within the last 3 months; * subject after stent implantation in superficial femoral artery; * subject with severe heart dysfunction, renal dysfunction, or cancer;
hr versus rfa for early stage hcc

Conditions: Hepatocellular Carcinoma; Liver Cancer

Summary: hepatocellular carcinoma (hcc) is the third leading death cancer in the world. it is important to explore a safe and effective therapy for early-stage hcc. previous studies reported that radiofrequency ablation (rfa) has higher efficacy and is associated with fewer complications and shorter hospital stays than hepatic resection (hr) for early-stage hcc. however, meta-analysis and systematic review found that rfa is associated with higher recurrence rate and lower long-term overall survival.


Eligibility criteria:
inclusion criteria: * age 18-75 years * clinical diagnosis of hcc was confirmed by histopathological examination of surgical samples in all patients * tumor stage fitted into milan criteria * patients have child-pugh a liver function * no previous neoadjuvant treatment * no evidence of metastasis to the lymph nodes and/or distant metastases on the basis of preoperative imaging results and perioperative findings * no malignancy other than hcc for 5 years prior to the initial hcc treatment * no history of encephalopathy, ascites refractory to diuretics or variceal bleeding exclusion criteria: * history of cardiac disease: * congestive heart failure \> new york heart association (nyha) class 2; active coronary artery disease (myocardial infarction more than 6 months prior to study entry is permitted); * cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers, calcium channel blocker or digoxin; or * uncontrolled hypertension (failure of diastolic blood pressure to fall below 90 mmhg, despite the use of 3 antihypertensive drugs). * active clinically serious infections ( \> grade 2 national cancer institute \[nci\]-common terminology criteria for adverse events version 3.0) * known history of human immunodeficiency virus (hiv) infection * known central nervous system tumors including metastatic brain disease * patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry * history of organ allograft * substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results * known or suspected allergy to the investigational agent or any agent given in association with this trial * any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study * pregnant or breast-feeding patients. women of childbearing potential must have a negative pregnancy test performed within seven days prior to the start of study drug. both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial. * excluded therapies and medications, previous and concomitant: * autologous bone marrow transplant or stem cell rescue within four months of start of study drug

Keywords: hepatocellular carcinoma liver cancer
the real world efficacy and safety of niraparib in korean women with primary and recurrent epithelial ovarian cancer

Conditions: Epithelial Ovarian Cancer

Summary: 1. to evaluate the efficacy and safety of niraparib in korean women with primary and recurrent epithelial ovarian cancer who underwent niraparib maintenance therapy 2. to evaluate the efficacy and safety of salvage niraparib therapy in korean women with heavily pretreated epithelial ovarian cancer.

it has been three years since niraparib was introduced into korea, and about 600 korean patients with epithelial ovarian cancer have been treated with this drug. the efficacy and safety of niraparib in primary and recurrent epithelial ovarian cancer were well demonstrated in the nova trial and the prima trial, and the efficacy and safety of niraparib in heavily pretreated epithelial ovarian cancer patients were confirmed in the -quadra trial. however, safety and efficacy data in korean women are still scanty. the purpose of this study was to evaluate the safety and efficacy of niraparib in korean women with primary and recurrent epithelial ovarian cancer.

Eligibility criteria:
inclusion criteria: * patients were diagnosed with all histologic type of epithelial ovarian cancer * observation cohort (cohort a): all patients who did not receive any kind of maintenance therapy for primary epithelial ovarian cancer from dec 2019 to dec 2022 * treatment cohort: epithelial ovarian cancer patients who treated with niraparib as maintenance treatment in any line from dec 2019 to dec 2022 * cohort b: all patients who received or who are receiving niraparib maintenance therapy for primary epithelial ovarian cancer in 1st line setting * cohort c: all patients who received or who are receiving niraparib maintenance therapy for recurrent epithelial ovarian cancer in 2nd or 3rd line setting * cohort d: all patients who received or who are receiving salvage niraparib therapy for recurrent epithelial ovarian cancer in 4th line or more line setting exclusion criteria: * borderline ovarian tumor * malignant ovarian germ cell tumor * malignant sex-cord stroma tumor * other malignancy within 5 years of diagnosis of epithelial ovarian cancer excluding carcinoma in situ of uterine cervix, endometrium, bladder, stomach, papillary thyroid cancer, and non-melanoma skin cancer
appendectomy in children performed by residents in the era of laparoscopic surgery

Conditions: Intraabdominal Abscess; Wound Infection

Summary: introduction: an increasing proportion of childhood appendicitis is treated with laparoscopic appendectomy (la). the investigators wanted to elucidate the outcome of childhood appendicitis treated primarily by residents in a university hospital. material and methods: all children (age\<16 years) treated surgically with appendectomy in our department between january 2006 and january 2011 were retrospectively identified. readmission, reoperation or postoperative length of stay (los) exceeding five days were considered as non-satisfactory outcomes.


Eligibility criteria:
inclusion criteria: * age below 16 years. operated on suspicion of appendicitis exclusion criteria: * appendectomy for causes other than suspicion of appendicitis

Keywords: los ileus fever reoperation
irinotecan plus cisplatin vs pemetrexed plus cisplatin as 2nd line in nsclc stage iiib/iv

Conditions: Non Small Cell Lung Cancer

Summary: this trial will compare the efficacy of irinotecan/cisplatin and pemetrexed/cisplatin in the second-line treatment of patients with stage iiib/iv nsclc

non-platinum-based doublets including the newer drugs can be used instead of platinum-based regimens in the first line treatment of patients with advanced nsclc. docetaxel or pemetrexed have been proven effective as second-line treatment of patients with nsclc. in a study conducted by our group the combination of irinotecan/cisplatin demonstrated higher response rates over cisplatin monotherapy in patients progressing after first-line docetaxel/gemcitabine. moreover, pemetrexed has been combined with the platinums (ie, cisplatin, carboplatin, and oxaliplatin) in nsclc to yield clinical activity similar to that of other platinum-based doublets. the efficacy of different platinum-based combinations in patients pretreated with non-platinum based first-line chemotherapy is not known.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed nsclc * age 18 -75 years * performance status (who) \<2 * patients progressing after first-line docetaxel/gemcitabine treatment * adequate bone marrow (absolute neutrophil count \>1000/mm3, platelet count \>100000/mm3, hemoglobin \> 9 gr/ mm3) * adequate liver (bilirubin \ 50mg/min) and cardiac (lvef \>50%) function * presence of measurable disease (according to resist criteria) * informed consent exclusion criteria: * psychiatric illness or social situation that would preclude study compliance' * other concurrent uncontrolled illness. * other invasive malignancy within the past 5 years except nonmelanoma skin cancer

Keywords: cancer nsclc second-line chemotherapy irinotecan pemetrexed
hiv testing and brief alcohol intervention for young drinkers in the emergency department

Conditions: Alcohol Consumption; Sexual Risk Behaviors

Summary: the purpose of this study was to determine whether a brief counseling intervention coupled with rapid hiv testing was feasible and effective at decreasing alcohol consumption and sexual risk behaviors among young, unhealthy drinkers presenting to the emergency department.


Eligibility criteria:
inclusion criteria: * 18-40 years old; * engaged in at least one sexual risk behavior in past 90 days; * alcohol consumption greater than niaaa guidelines for at-risk drinking; * unknown or negative hiv status and willing to be tested; * able to provide contact information for follow-up; * able to provide written informed consent. exclusion criteria: * known hiv positive status; * medically or psychiatrically unstable.

Keywords: alcohol consumption sexual risk behaviors young, unhealthy drinkers